Cian McCarthy

For symptomatic patients who’ve undergone CCTA, added knowledge gleaned from AI-CPA (@Heartflow) changes the management strategy more than half the time, according to new data from the DECIDE registry. tctmd.com/news/ai-based-… @CianPMcCarthy @SuzanneJBaron #SCCT2025

Thank you so much @AnasAAlani ! Grateful to @Cleerlyhealth for sponsoring this award and @Heartflow for funding this study. It was an honor to accept this award on behalf of the DECIDE investigators @lesleejshaw @RonBlankstein

SCCT is proud to announce the 2025 CTRA winner - Dr. @CianPMcCarthy - for his groundbreaking work on AI in atherosclerotic plaque management! Learn more: ow.ly/EBIP50Wilxi

Our paper on #cardiac #troponins and #coronary #atherosclerosis in Masters #athletes just got published in @JACCJournals. Download your copy via: authors.elsevier.com/a/1lH6h2d9GI28… #sportscardio #exercise #prevention

Now in @JACCJournals, @ThijsEijsvogels and colleagues find that most exercise induced troponin elevation is not explainable by CAD. jacc.org/doi/10.1016/j.… @MeaganWasfy and I contextualize these results in accompanying editorial @MGHHeartHealth jacc.org/doi/10.1016/j.…

While this content may seem obvious @ first, I humbly believe the idea is more nuanced than first glance and rather profound. Led by @CianPMcCarthy. @NIPCIRELAND @rblument1 Reflections on Binary Thresholds for Hypercholesterolemia and Hypertension | JACC jacc.org/doi/10.1016/j.…

Now in @JACCJournals, @johnwmcevoy and I discuss approaches to defining hypercholesterolemia and hypertension in an era of CVD risk based treatment allocation. jacc.org/doi/full/10.10…

Last dinner as an Advanced Cardiac Imaging fellow. Grateful for amazing colleagues, inspiring mentors, and a world-class hospital. Onward, with deep gratitude. ❤️🫀 #FellowshipGraduation #CardiacImaging #MGH @CIRC_MGH

In this Viewpoint, @CianPMcCarthy and colleagues advocate for cardiovascular disease outcome trials for new BP lowering treatments targeting novel pathways. ja.ma/3H6NBsg

@NIPCIRELAND @GalwayCMNHS @CiccaroneCenter led by @CianPMcCarthy Regulatory Approval vs Guideline Endorsement of Novel BP-Lowering Treatments jamanetwork.com/journals/jamac…

After 20 years of static development, 3 novel BP ⬇️ therapies were FDA approved in 2024. Now in @JAMACardio, led by ⭐️ @UMassChan student Ritika Revoori, we discuss whether BP surrogate endpoint trials are sufficient for endorsement. @johnwmcevoy jamanetwork.com/journals/jamac…

Ever get annoyed working up mildly elevated troponins in older adults who do not have signs of myocardial ischemia? Turns out many of those ‘mildly elevated’ troponins in persons in 70s and 80s are likely within NORMAL RANGE for their age. Huge issue! academic.oup.com/eurheartj/adva…

The TARGET-Type 2 pilot RCT demonstrates it is feasible to randomise patients with Type 2 MI to CTCA and echocardiography guided treatment of coronary artery disease and LV impairment 🧵sciencedirect.com/science/articl…

Dreams do come true.

Today means everything

Our new meta-analysis in @JACCJournals @hmkyale led by @anoopshah17: Cardiac Troponins and CV Risk Prediction! Measurement of cardiac troponin results in a modest improvement in the prediction of first-onset CVD. jacc.org/doi/full/10.10… @CTCPR_ @RigsHeart @DLBHATTMD

In this weeks edition of @JACCJournals, Dr. Shah and colleagues explore the use of hs-cTn in CVD risk prediction for primary prevention. jacc.org/doi/10.1016/j.… Drs. Januzzi, @johnwmcevoy, and I discuss the implication of their findings. jacc.org/doi/10.1016/j.…